疑似前列腺癌患者行~(68)Ga-PSMA-11 PET/CT检查的护理
|
摘要
对6例怀疑前列腺癌患者采用新型肿瘤显像剂~(68)Ga-PSMA-11行PET/CT检查,以~(18)F-FDG护理方法为参考,依据~(68)Ga-PSMA-11药理作用特点调整护理方法,均顺利完成检查并获得满意的诊断图像。提示~(68)Ga-PSMA-11用于PET/CT检查可部分参考~(18)F-FDG护理方法,但具有自己的特色,不需要禁食禁饮、不需要测空腹血糖、显像剂可与呋噻米同时静脉注射等。
引文
[1] 韩苏军,张思维,陈万青,等.中国前列腺癌死亡现状及流行趋势分析[J].中华泌尿外科杂志,2012,33(11):836-839.
[2] Gordon I O,Tretiakova M S,Noffsinger A E,et al.Prostate-specific membrane antigen expression in regeneration and repair[J].Mod Pathol,2008,21(12):1421-1427.
[3] Perner S,Hofer M D,Kim R,et al.Prostate-specific membrane antigen expression as a predictor of prostate cancer progression[J].Human Pathol,2007,38(5):696-701.
[4] Afsharoromieh A,Malcher A,Eder M,et al.PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer:biodistribution in humans and first evaluation of tumour lesions[J].Eur J Nucl Med Mol Imaging,2013,40(5):797-798.
[5] Eder M,Neels O,Müller M,et al.Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC:a new PET tracer for imaging of prostate cancer[J].Pharmaceuticals,2014,7(7):779.
[6] 崔璨,邵国强,徐志红,等.68Ga-PSMA-11 标记合成及生物分布和代谢动力学研究[J].中华核医学与分子影像杂志,2016,36(2):106-111.
[7] 臧士明,王峰,黄悦,等.68Ga-PSMA-11 PET/CT对去势抵抗性前列腺癌的诊断价值[J].中华核医学与分子影像杂志,2017,37(3):142-146.
[8] 刘蕊,潜海滨,李楠,等.PET/CT检查的护理配合[J].护理学杂志,2006,21(19):43-44.
[9] 黄薇,向美焕,罗永.规范化护理在PET/CT显像检查中的应用[J].岭南急诊医学杂志,2018,23(4):398-399.
[10] 张彦彬,朱家瑞.钡餐造影致18F-FDG符合线路显像假阳性一例[J].中华核医学与分子影像杂志,2005,25(5):300.
[11] 叶定伟,张海梁,姚旭东,等.多西他赛联合泼尼松或米托蒽醌联合泼尼松治疗激素抵抗性前列腺癌[J].中国癌症杂志,2007,17(3):236-239.
[12] 王婷婷,刘敏,张玉,等.恩杂鲁胺:治疗转移性去势抵抗性前列腺癌的新药[J].中国新药与临床杂志,2017,36(5):245-248.
[13] 薛新力,朱龚萍,陈良英.临床心理护理基本概念与方法评析[J].护理学杂志,2010,25(24):79-81.
[14] Sprinz C,Altmayer S,Zanon M,et al.Effects of blood glucose level on 18F-FDG uptake for PET/CT in normal organs:a systematic review[J].PLoS One,2018,13(2):e0193140.
[15] 王风.核医学检查受检者所受辐射剂量分析[J].中华放射医学与防护杂志,2015,35(9):705-708.
[16] Afshar-Oromieh A,Avtzi E,Giesel F L,et al.The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer[J].Eur J Nucl Med Mol Imaging,2015,42(2):197-209.
[2] Gordon I O,Tretiakova M S,Noffsinger A E,et al.Prostate-specific membrane antigen expression in regeneration and repair[J].Mod Pathol,2008,21(12):1421-1427.
[3] Perner S,Hofer M D,Kim R,et al.Prostate-specific membrane antigen expression as a predictor of prostate cancer progression[J].Human Pathol,2007,38(5):696-701.
[4] Afsharoromieh A,Malcher A,Eder M,et al.PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer:biodistribution in humans and first evaluation of tumour lesions[J].Eur J Nucl Med Mol Imaging,2013,40(5):797-798.
[5] Eder M,Neels O,Müller M,et al.Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC:a new PET tracer for imaging of prostate cancer[J].Pharmaceuticals,2014,7(7):779.
[6] 崔璨,邵国强,徐志红,等.68Ga-PSMA-11 标记合成及生物分布和代谢动力学研究[J].中华核医学与分子影像杂志,2016,36(2):106-111.
[7] 臧士明,王峰,黄悦,等.68Ga-PSMA-11 PET/CT对去势抵抗性前列腺癌的诊断价值[J].中华核医学与分子影像杂志,2017,37(3):142-146.
[8] 刘蕊,潜海滨,李楠,等.PET/CT检查的护理配合[J].护理学杂志,2006,21(19):43-44.
[9] 黄薇,向美焕,罗永.规范化护理在PET/CT显像检查中的应用[J].岭南急诊医学杂志,2018,23(4):398-399.
[10] 张彦彬,朱家瑞.钡餐造影致18F-FDG符合线路显像假阳性一例[J].中华核医学与分子影像杂志,2005,25(5):300.
[11] 叶定伟,张海梁,姚旭东,等.多西他赛联合泼尼松或米托蒽醌联合泼尼松治疗激素抵抗性前列腺癌[J].中国癌症杂志,2007,17(3):236-239.
[12] 王婷婷,刘敏,张玉,等.恩杂鲁胺:治疗转移性去势抵抗性前列腺癌的新药[J].中国新药与临床杂志,2017,36(5):245-248.
[13] 薛新力,朱龚萍,陈良英.临床心理护理基本概念与方法评析[J].护理学杂志,2010,25(24):79-81.
[14] Sprinz C,Altmayer S,Zanon M,et al.Effects of blood glucose level on 18F-FDG uptake for PET/CT in normal organs:a systematic review[J].PLoS One,2018,13(2):e0193140.
[15] 王风.核医学检查受检者所受辐射剂量分析[J].中华放射医学与防护杂志,2015,35(9):705-708.
[16] Afshar-Oromieh A,Avtzi E,Giesel F L,et al.The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer[J].Eur J Nucl Med Mol Imaging,2015,42(2):197-209.